Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of GSK2586881 on Hypoxia and Exercise Response
NCT03000686Phase 1Terminated
- Sponsor
- GSK
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alunacedase alfa in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GSK. Primary endpoint: Pulmonary Artery Systolic Pressure. Started May 2017; status: terminated.
02
Drugs
alunacedase alfa
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03000686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000686.